Drug Profile
Obefazimod - Abivax
Alternative Names: ABX-464; SPL-464Latest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator Splicos
- Developer Abivax
- Class Amines; Anti-inflammatories; Antirheumatics; Antivirals; Chlorobenzenes; Fluorobenzenes; Quinolines; Small molecules
- Mechanism of Action MiRNA-124 expression stimulants; RNA cap-binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Ulcerative colitis
- Phase II/III COVID 2019 infections
- Phase II Rheumatoid arthritis
- Phase I Crohn's disease
- Discontinued HIV infections
Most Recent Events
- 13 Feb 2024 Abivax plans a phase IIb trial for Crohn's disease in the third quarter of 2024
- 31 Oct 2023 Abivax plans a clinical trial for Ulcerative colitis (Combination therapy) in 2025 (Abivax pipeline, October 2023)
- 14 Oct 2023 Efficacy and adverse events data from a phase IIb trial in Ulcerative colitis presented at the 31st United European Gastroenterology Week (UEG-2023)